Home / Market News / $ALMS

$ALMS news and market catalysts

The 8 most recent market catalysts affecting $ALMS, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.

8 catalysts 2 high impact 1 bullish 6 bearish Biotechnology
Sep 3, 2026 Corporate Catalyst Bearish Impact 65
Guggenheim Downgrades Alumis to Neutral
Guggenheim analyst Yatin Suneja downgraded Alumis (ALMS) from a 'Buy' to 'Neutral' rating. This change in analyst recommendation signals a shift in the firm's outlook on Alumis's f…
Sep 2, 2026 Corporate Catalyst Bearish Impact 65
Oppenheimer Maintains Outperform on Alumis, Lowers Price Target to $37
Oppenheimer analyst Jeff Jones has reduced the price target for Alumis (ALMS) from $55 to $37, although the 'Outperform' rating was maintained. This action indicates that while the…
Sep 2, 2026 Corporate Catalyst Bearish Impact 65
Wells Fargo Maintains Overweight on Alumis, Lowers Price Target to $25
Wells Fargo analyst Derek Archila maintained an 'Overweight' rating on Alumis but drastically cut the price target from $51 to $25. This move suggests that while the analyst still …
Sep 2, 2026 Corporate Catalyst Bearish Impact 55
Morgan Stanley Maintains Overweight on Alumis, Lowers Price Target to $29
Morgan Stanley analyst Terence Flynn maintained an 'Overweight' rating on Alumis, signaling continued confidence in the company's fundamentals. However, the price target was lowere…
Sep 1, 2026 Corporate Catalyst Bearish Impact 95
Why Is Alumis Stock Falling Tuesday?
Alumis Inc. experienced a massive stock decline after its envudeucitinib drug failed to meet primary and secondary endpoints in a Phase 2b trial for systemic lupus erythematosus. T…
Sep 1, 2026 Corporate Catalyst Neutral Impact 55
ALUMIS INC. files 8-K with SEC
An 8-K filing is a mandatory disclosure by U.S. public companies to report significant events that shareholders should know about. While the headline itself doesn't specify the con…
Aug 13, 2026 Corporate Catalyst Bearish Impact 92
Alumis Q2 EPS $(1.11) Misses $(0.71) Estimate, Sales $1.662M Miss $3.468M Estimate
Alumis (ALMS) announced Q2 earnings per share of $(1.11), missing the consensus estimate of $(0.71) by a wide margin, and sales of $1.662 million, falling short of the $3.468 milli…
Aug 11, 2026 Corporate Catalyst Bullish Impact 75
Alumis Psoriasis Treatment Shows Leading Skin Clearance Rates
Alumis Inc. announced impressive long-term data from its ONWARD3 study for envudeucitinib, an oral treatment for plaque psoriasis. The drug achieved high PASI 100 response rates an…
 Join the waitlist for full signal validation →

New to reading filings? What an SEC 8-K is and why it moves prices

Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.